$ZOM
Zomedica Corp.

2020 Q2 Form 10-Q Financial Statement

#000117184320005784 Filed on August 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 Q1 2019 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $1.394M $1.703M $1.133M
YoY Change 23.07% -57.1% -28.29%
% of Gross Profit
Research & Development $3.908M $630.1K $1.062M
YoY Change 268.17% -91.63% -58.12%
% of Gross Profit
Depreciation & Amortization $77.86K $76.42K $68.93K
YoY Change 12.96% 23.14% 151.01%
% of Gross Profit
Operating Expenses $5.303M $2.334M $1.062M
YoY Change 399.53% -69.02% -58.12%
Operating Profit -$5.303M -$2.334M -$2.391M
YoY Change 121.77% -80.04% -42.35%
Interest Expense $0.00 $651.00 $12.16K
YoY Change -100.0% -89.46%
% of Operating Profit
Other Income/Expense, Net $0.00 $5.500K
YoY Change
Pretax Income -$5.308M -$2.451M -$2.404M
YoY Change 120.76% -79.01% -41.98%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$5.308M -$2.451M -$2.404M
YoY Change 120.76% -79.01% -41.98%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$24.71K -$20.71K -$22.26K
COMMON SHARES
Basic Shares Outstanding 214.8M 118.3M 108.0M
Diluted Shares Outstanding 214.8M 118.3M 108.0M

Balance Sheet

Concept 2020 Q2 2020 Q1 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.10M $1.497M $5.822M
YoY Change 399.87% -34.83% 36.03%
Cash & Equivalents $29.10M $1.497M $6.982M
Short-Term Investments
Other Short-Term Assets $782.7K $520.3K $1.389M
YoY Change -43.66% -53.29% 21.86%
Inventory
Prepaid Expenses
Receivables $182.5K $142.5K $95.55K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $30.07M $2.160M $7.307M
YoY Change 311.51% -38.1% 33.73%
LONG-TERM ASSETS
Property, Plant & Equipment $798.9K $75.23K $794.4K
YoY Change 0.57% -91.24% 78.63%
Goodwill
YoY Change
Intangibles $453.4K $498.4K $12.52K
YoY Change 3520.88% 3796.17% -9.02%
Long-Term Investments
YoY Change
Other Assets $7.300K
YoY Change -98.54%
Total Long-Term Assets $2.693M $2.875M $2.173M
YoY Change 23.97% 19.51% 127.74%
TOTAL ASSETS
Total Short-Term Assets $30.07M $2.160M $7.307M
Total Long-Term Assets $2.693M $2.875M $2.173M
Total Assets $32.76M $5.035M $9.479M
YoY Change 245.61% -14.58% 47.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.204M $1.579M $1.797M
YoY Change -32.99% -79.69% 6.95%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $527.4K $0.00 $0.00
YoY Change
Long-Term Debt Due $232.5K $222.8K
YoY Change
Total Short-Term Liabilities $1.964M $1.802M $1.797M
YoY Change 9.3% -76.82% 6.71%
LONG-TERM LIABILITIES
Long-Term Debt $1.219M $1.281M $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $1.219M $1.281M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.964M $1.802M $1.797M
Total Long-Term Liabilities $1.219M $1.281M $0.00
Total Liabilities $3.183M $3.083M $1.797M
YoY Change 77.13% -60.34% 6.95%
SHAREHOLDERS EQUITY
Retained Earnings -$59.82M -$54.51M -$46.36M
YoY Change 29.04% 24.02% 111.26%
Common Stock $75.97M $44.50M $42.07M
YoY Change 80.56% 5.77% 57.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $29.58M $1.952M $7.683M
YoY Change
Total Liabilities & Shareholders Equity $32.76M $5.035M $9.479M
YoY Change 245.61% -14.58% 47.7%

Cashflow Statement

Concept 2020 Q2 2020 Q1 2019 Q2
OPERATING ACTIVITIES
Net Income -$5.308M -$2.451M -$2.404M
YoY Change 120.76% -79.01% -41.98%
Depreciation, Depletion And Amortization $77.86K $76.42K $68.93K
YoY Change 12.96% 23.14% 151.01%
Cash From Operating Activities -$5.721M -$2.173M -$8.436M
YoY Change -32.19% -15.81% 207.83%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $1.008M
YoY Change
Cash From Investing Activities $1.008M -$5.477K
YoY Change -1558.33% -95.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $24.00M $2.500M $0.00
YoY Change -16.67% -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 33.33M 2.152M 11.97M
YoY Change 178.49% -28.44% 198.49%
NET CHANGE
Cash From Operating Activities -5.721M -2.173M -8.436M
Cash From Investing Activities 1.008M -5.477K
Cash From Financing Activities 33.33M 2.152M 11.97M
Net Change In Cash 27.61M 986.2K 3.525M
YoY Change 683.06% 176.65% 208.1%
FREE CASH FLOW
Cash From Operating Activities -$5.721M -$2.173M -$8.436M
Capital Expenditures
Free Cash Flow -$5.721M -$2.173M -$8.436M
YoY Change -32.19% -18.01% 194.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1731469
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2087525
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
1731469
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
2087525
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
182496
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
67618
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
270405
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
546654
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
612046
CY2019 us-gaap Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1
AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
901
us-gaap Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1
AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
88883
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
8639590
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3625083
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2341104
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
290866
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
135844
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
290866
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2341104
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1082
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
90025
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
44990
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
270
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
537
CY2020Q2 us-gaap Assets
Assets
32761587
CY2019Q4 us-gaap Assets
Assets
4182984
CY2020Q2 us-gaap Assets Current
AssetsCurrent
30068192
CY2019Q4 us-gaap Assets Current
AssetsCurrent
1806789
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 0"></td> <td style="width: 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">2.</div></div></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Basis of preparation</div></td> </tr> </table> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">The accounting policies set out below have been applied consistently in the condensed unaudited interim consolidated financial statements. The condensed unaudited interim consolidated financial statements do <div style="display: inline; font-style: italic; font: inherit;">not</div> include all of the information required for annual consolidated financial statements and should be read in conjunction with the Company's audited consolidated financial statements for the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019. </div>In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the <div style="display: inline; font-style: italic; font: inherit;">three</div> and <div style="display: inline; font-style: italic; font: inherit;">six</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020 </div>are <div style="display: inline; font-style: italic; font: inherit;">not</div> necessarily indicative of the results that <div style="display: inline; font-style: italic; font: inherit;"> may </div>be expected for the year ending <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020.</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"></div> <table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="text-align: justify"><div style="display: inline; font-weight: bold;"></div></td> </tr> </table> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">These condensed unaudited interim consolidated financial statements were prepared using the same basis of presentation, accounting policies and methods of computation as those of the audited consolidated financial statements for the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019.</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; font-style: italic;">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; font-style: italic;">Basis of consolidation</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">These condensed unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned operating subsidiary, Zomedica Pharmaceuticals, Inc.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">All inter-company accounts and transactions have been eliminated on consolidation.</div></div>
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1496752
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2296731
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
510586
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1940265
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29103049
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5822148
CY2020Q2 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
27606297
CY2019Q2 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3525417
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
28592463
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3881883
CY2020Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2019Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2019 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
361039946
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
108038398
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
361039946
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
108038398
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
67328922
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
38566820
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
108
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1089
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1089
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2020Q2 us-gaap Deposit Assets
DepositAssets
655203
CY2019Q4 us-gaap Deposit Assets
DepositAssets
1033231
CY2020Q2 us-gaap Depreciation
Depreciation
77859
CY2019Q2 us-gaap Depreciation
Depreciation
68925
us-gaap Depreciation
Depreciation
154275
us-gaap Depreciation
Depreciation
130979
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
277150
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
154275
CY2020Q2 us-gaap Depreciation Nonproduction
DepreciationNonproduction
77859
CY2019Q2 us-gaap Depreciation Nonproduction
DepreciationNonproduction
68925
us-gaap Depreciation Nonproduction
DepreciationNonproduction
154275
us-gaap Depreciation Nonproduction
DepreciationNonproduction
130979
CY2020Q2 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
1731469
CY2019Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
2087525
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8321
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9403
CY2020Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
99428
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
180144
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
90796
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2020Q2 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
40032
CY2019Q2 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
17578
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
114878
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
180144
CY2018Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
21379
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
552798
CY2020Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
552798
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
453370
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
543395
CY2019 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
531419
us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
CY2020Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-5692
CY2019Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
58
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1279
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1283
CY2020Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
CY2019Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-1308
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-69834
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-1308
CY2020Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-69834
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-69834
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
988734
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
901319
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2272261
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4113677
CY2020Q1 us-gaap Impaired Assets To Be Disposed Of By Method Other Than Sale Carrying Value Of Asset
ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset
5400
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5307990
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2404427
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7758607
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14081337
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
41891
CY2020Q2 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-374859
CY2019Q2 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5977134
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-883414
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-579716
CY2020Q2 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
318643
CY2019Q2 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
327138
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-78762
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
98075
CY2019Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-92418
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-67908
CY2020Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-56284
CY2019Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
CY2020Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
453370
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
543395
CY2020Q2 us-gaap Interest Expense
InterestExpense
CY2019Q2 us-gaap Interest Expense
InterestExpense
12164
us-gaap Interest Expense
InterestExpense
732
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-263010
CY2020Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
CY2019Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
CY2020Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
us-gaap Interest Expense
InterestExpense
18338
CY2020Q2 us-gaap Interest Income Operating
InterestIncomeOperating
247
CY2019Q2 us-gaap Interest Income Operating
InterestIncomeOperating
us-gaap Interest Income Operating
InterestIncomeOperating
328
us-gaap Interest Income Operating
InterestIncomeOperating
CY2020Q2 us-gaap Interest Paid Net
InterestPaidNet
CY2019Q2 us-gaap Interest Paid Net
InterestPaidNet
12164
us-gaap Interest Paid Net
InterestPaidNet
651
us-gaap Interest Paid Net
InterestPaidNet
18338
CY2020Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
CY2019Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
792104
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1905045
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
400133
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
36326
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
437236
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
424501
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
412137
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
194712
CY2020Q2 us-gaap Liabilities
Liabilities
3182626
CY2019Q4 us-gaap Liabilities
Liabilities
2087525
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32761587
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4182984
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1963965
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2087525
CY2020Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33326825
CY2019Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11966905
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35478602
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14973733
CY2020Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
CY2019Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5477
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1007513
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-74563
CY2020Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5720528
CY2019Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8436011
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7893652
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11017287
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-5307990
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-2404427
us-gaap Net Income Loss
NetIncomeLoss
-7758607
us-gaap Net Income Loss
NetIncomeLoss
-14081337
CY2020Q2 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
CY2020Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
CY2019Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
CY2019Q2 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
59097
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1451157
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
232496
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1218661
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
5500
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
CY2020Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
74079
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
64889
CY2020Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2491177
CY2019Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
33095
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5302545
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2391013
us-gaap Operating Income Loss
OperatingIncomeLoss
-7636051
us-gaap Operating Income Loss
OperatingIncomeLoss
-14082711
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
us-gaap Operating Lease Payments
OperatingLeasePayments
162260
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1441124
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1103658
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
42448
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
254690
CY2020Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
CY2019Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
127345
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2839400
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
626267
CY2020Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2019Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2020Q2 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2019Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
12
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
12
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
12
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
12
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
11961397
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
11961397
CY2020Q2 us-gaap Prepaid Advertising
PrepaidAdvertising
33505
CY2019Q4 us-gaap Prepaid Advertising
PrepaidAdvertising
19829
CY2020Q2 us-gaap Prepaid Insurance
PrepaidInsurance
19860
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
110636
CY2020Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23998783
CY2019Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
26498783
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3000000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1275796
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1410947
us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
CY2020Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2019Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
600000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75234
CY2020Q2 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
CY2019Q2 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
12000000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
12000000
CY2020Q2 us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
CY2019Q2 us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
5400
CY2020Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9826359
CY2019Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9826359
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
600000
CY2020Q2 us-gaap Professional Fees
ProfessionalFees
282791
CY2019Q2 us-gaap Professional Fees
ProfessionalFees
231647
us-gaap Professional Fees
ProfessionalFees
573472
us-gaap Professional Fees
ProfessionalFees
989946
CY2019 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
290513
us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
299268
CY2019 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
2210
us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
164117
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
987493
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
729142
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
798901
us-gaap Reclassifications
Reclassifications
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">23.</div> Comparative figures </div></div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had <div style="display: inline; font-style: italic; font: inherit;">no</div> effect on the reported results of operations. Adjustments have been made to the consolidated schedule of expenses for the <div style="display: inline; font-style: italic; font: inherit;">three</div> and <div style="display: inline; font-style: italic; font: inherit;">six</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2019, </div>to classify health insurance benefits as part of salaries, wages and bonuses and audit fees to professional fees. This change in classification does <div style="display: inline; font-style: italic; font: inherit;">not</div> affect previously reported cash flows from operating activities in the consolidated statements of cash flows.</div></div>
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3908171
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1061507
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4503570
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8592882
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59816448
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52057841
CY2020Q2 us-gaap Share Based Compensation
ShareBasedCompensation
135844
CY2019Q2 us-gaap Share Based Compensation
ShareBasedCompensation
us-gaap Share Based Compensation
ShareBasedCompensation
290866
us-gaap Share Based Compensation
ShareBasedCompensation
2341104
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.19
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.19
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
1.52
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.87
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.68
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0021
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0049
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0256
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
50000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
5000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
50000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
150000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
15000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
30000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
15000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
15000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2000000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
7056000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5995000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5056000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2000000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7040265
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13766265
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.28
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.73
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.52
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.12
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.52
CY2020Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.19
CY2019Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.19
CY2020Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.52
CY2020Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.52
CY2020Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.52
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.19
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
4960333
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
8805932
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.04
CY2020Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2020Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.19
CY2020Q2 us-gaap Share Price
SharePrice
0.19
CY2020Q1 us-gaap Share Price
SharePrice
0.18
CY2019Q1 us-gaap Share Price
SharePrice
1.23
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
394735
CY2019Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
792104
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
27964283
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
600000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3657000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
7682604
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
2095459
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
29578961
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; font-style: italic;">Use of estimates</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">The preparation of the condensed unaudited interim consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed unaudited interim consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Areas where significant judgment is involved in making estimates are, the determination of fair value of stock-based compensation, the useful lives of property and equipment, allocation of proceeds from financings to shares and warrants, fair value of placement agent warrants and forecasting future cash flows for assessing the going concern assumption.</div></div></div></div></div></div></div></div></div></div>
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
214830818
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108038398
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
166814645
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
104528705
CY2020Q2 zom Accounts Payable And Accrued Liabilities Due In3 To6 Months
AccountsPayableAndAccruedLiabilitiesDueIn3To6Months
CY2019Q4 zom Accounts Payable And Accrued Liabilities Due In3 To6 Months
AccountsPayableAndAccruedLiabilitiesDueIn3To6Months
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
214830818
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
108038398
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
166814645
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
104528705
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
214830818
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108038398
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
166814645
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
104528705
CY2020Q2 zom Accounts Payable And Accrued Liabilities Due Greater Than1 Year
AccountsPayableAndAccruedLiabilitiesDueGreaterThan1Year
CY2019Q4 zom Accounts Payable And Accrued Liabilities Due Greater Than1 Year
AccountsPayableAndAccruedLiabilitiesDueGreaterThan1Year
CY2020Q2 zom Accounts Payable And Accrued Liabilities Due In6 To9 Months
AccountsPayableAndAccruedLiabilitiesDueIn6To9Months
CY2019Q4 zom Accounts Payable And Accrued Liabilities Due In6 To9 Months
AccountsPayableAndAccruedLiabilitiesDueIn6To9Months
CY2020Q2 zom Accounts Payable And Accrued Liabilities Due In9 To12 Months
AccountsPayableAndAccruedLiabilitiesDueIn9To12Months
CY2020Q2 zom Accounts Payable And Accrued Liabilities Due Less Than3 Months
AccountsPayableAndAccruedLiabilitiesDueLessThan3Months
1731469
CY2019Q4 zom Accounts Payable And Accrued Liabilities Due Less Than3 Months
AccountsPayableAndAccruedLiabilitiesDueLessThan3Months
2087525
zom Adjustments To Equity Warrant Issued
AdjustmentsToEquityWarrantIssued
zom Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
108032613
CY2020Q2 zom Due To Related Parties3 To6 Months
DueToRelatedParties3To6Months
CY2019Q4 zom Due To Related Parties3 To6 Months
DueToRelatedParties3To6Months
CY2020Q2 zom Due To Related Parties6 To9 Months
DueToRelatedParties6To9Months
CY2019Q4 zom Due To Related Parties6 To9 Months
DueToRelatedParties6To9Months
CY2020Q2 zom Due To Related Parties9 To12 Months
DueToRelatedParties9To12Months
CY2019Q4 zom Due To Related Parties9 To12 Months
DueToRelatedParties9To12Months
CY2020Q2 zom Due To Related Parties Greater Than1 Year
DueToRelatedPartiesGreaterThan1Year
CY2019Q4 zom Due To Related Parties Greater Than1 Year
DueToRelatedPartiesGreaterThan1Year
CY2020Q2 zom Due To Related Parties Less Than3 Months
DueToRelatedPartiesLessThan3Months
1731469
CY2019Q4 zom Due To Related Parties Less Than3 Months
DueToRelatedPartiesLessThan3Months
2087525
CY2020Q2 zom Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
CY2019Q2 zom Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
zom Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
zom Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
19737
CY2020Q1 zom Issuance Of Common Shares And Warrants Direct Costs Of Issuance
IssuanceOfCommonSharesAndWarrantsDirectCostsOfIssuance
348220
CY2020Q2 zom Issuance Of Common Shares And Warrants Direct Costs Of Issuance
IssuanceOfCommonSharesAndWarrantsDirectCostsOfIssuance
582977
CY2020Q2 zom Issuance Of Common Shares And Warrants Direct Costs Of Issuance
IssuanceOfCommonSharesAndWarrantsDirectCostsOfIssuance
1908202
zom Issuance Of Common Shares And Warrants Direct Costs Of Issuance
IssuanceOfCommonSharesAndWarrantsDirectCostsOfIssuance
2839400
CY2020Q2 zom Noncash Rent Expense
NoncashRentExpense
6019
CY2019Q2 zom Noncash Rent Expense
NoncashRentExpense
zom Noncash Rent Expense
NoncashRentExpense
10032
zom Noncash Rent Expense
NoncashRentExpense
CY2019Q4 zom Number Of Lease Agreements
NumberOfLeaseAgreements
2
zom Operating Lease Liability Additions
OperatingLeaseLiabilityAdditions
1553612
zom Operating Lease Liability Interest
OperatingLeaseLiabilityInterest
59805
CY2020Q2 zom Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
112487
CY2020Q2 zom Operating Lease Right Of Use Asset Aggregate Lease Commitments
OperatingLeaseRightOfUseAssetAggregateLeaseCommitments
2067505
zom Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
172292
CY2020Q2 zom Operating Lease Right Of Use Asset Cost
OperatingLeaseRightOfUseAssetCost
1553611
CY2020Q2 zom Operating Lease Right Of Use Asset Impact Of Present Value
OperatingLeaseRightOfUseAssetImpactOfPresentValue
513894
zom Proceeds For Government Loan
ProceedsForGovernmentLoan
527360
zom Proceeds For Government Loan
ProceedsForGovernmentLoan
CY2020Q2 zom Proceeds From Pending Warrant Exercises
ProceedsFromPendingWarrantExercises
1465500
CY2019Q2 zom Proceeds From Pending Warrant Exercises
ProceedsFromPendingWarrantExercises
zom Proceeds From Pending Warrant Exercises
ProceedsFromPendingWarrantExercises
1465500
zom Proceeds From Pending Warrant Exercises
ProceedsFromPendingWarrantExercises
CY2020Q2 zom Proceeds From Refund Of Prepaid Rent
ProceedsFromRefundOfPrepaidRent
zom Stock Issued During Period Value Exercise Of Warrants And Prefunded Warrants
StockIssuedDuringPeriodValueExerciseOfWarrantsAndPrefundedWarrants
9826360
zom Stock Issued During Period Value Issued For Financing Net Of Cost
StockIssuedDuringPeriodValueIssuedForFinancingNetOfCost
14373733
CY2019Q2 zom Proceeds From Refund Of Prepaid Rent
ProceedsFromRefundOfPrepaidRent
-5477
zom Proceeds From Refund Of Prepaid Rent
ProceedsFromRefundOfPrepaidRent
1002113
zom Proceeds From Refund Of Prepaid Rent
ProceedsFromRefundOfPrepaidRent
-74563
CY2020Q2 zom Property Plant And Equipment Including Leased Assets
PropertyPlantAndEquipmentIncludingLeasedAssets
2240025
CY2019Q4 zom Property Plant And Equipment Including Leased Assets
PropertyPlantAndEquipmentIncludingLeasedAssets
1832800
CY2020Q2 zom Stock Issued During Period Shares Exercise Of Warrants And Prefunded Warrants
StockIssuedDuringPeriodSharesExerciseOfWarrantsAndPrefundedWarrants
12162492
zom Operating Lease Rightofuse Asset Interest
OperatingLeaseRightofuseAssetInterest
-59805
CY2020Q2 zom Pending Warrant Exercises
PendingWarrantExercises
1465500
CY2019Q4 zom Pending Warrant Exercises
PendingWarrantExercises
CY2020Q2 zom Prepaid Expenses And Deposits
PrepaidExpensesAndDeposits
782647
CY2019Q4 zom Prepaid Expenses And Deposits
PrepaidExpensesAndDeposits
1228585
CY2020Q2 zom Prepaid Expenses And Deposits Current
PrepaidExpensesAndDepositsCurrent
782647
CY2019Q4 zom Prepaid Expenses And Deposits Current
PrepaidExpensesAndDepositsCurrent
1228585
CY2020Q2 zom Proceeds For Government Loan
ProceedsForGovernmentLoan
527360
CY2019Q2 zom Proceeds For Government Loan
ProceedsForGovernmentLoan

Files In Submission

Name View Source Status
0001171843-20-005784-index-headers.html Edgar Link pending
0001171843-20-005784-index.html Edgar Link pending
0001171843-20-005784.txt Edgar Link pending
0001171843-20-005784-xbrl.zip Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10q_081020p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zom-20200630.xml Edgar Link completed
zom-20200630.xsd Edgar Link pending
zom-20200630_cal.xml Edgar Link unprocessable
zom-20200630_def.xml Edgar Link unprocessable
zom-20200630_lab.xml Edgar Link unprocessable
zom-20200630_pre.xml Edgar Link unprocessable